Study Results

 
News Articles for Study Results top ^
2015/1/8
Biogen Idec's (BIIB) stock was up 6.2% after the company reported Thursday that a treatment for acute optic neuritis it has developed proved to be effective in the second phase of a research study.
Sign-up for Biogen rises 6.2% after strong study results investment picks
2015/1/13
Teleflex Incorporated (NYSE: TFX), a leading global provider of medical devices for critical care and surgery, announced that newly published research has reaffirmed the ability of catheters protected with ARROWg + ard ® Technology to reduce both bloodstream infections and direct costs associated with treating those infections.
Sign-up for Teleflex Reports Study Results of ARROWg+ard® Technology Effectiveness in Preventing Infections and Associated Costs in an Infection-Prone Insertion Site investment picks
2015/2/4
http://www.ccnmatthews.com/logos/20100223-inv200.jpg TORONTO, ONTARIO --
Sign-up for INV Metals Announces Positive Preliminary Feasibility Study Results for the Loma Larga Gold Project investment picks
2015/1/27
Dominion Diamond Corporation (TSX: DDC, NYSE: DDC) (the “Company” or “Dominion”) is pleased to announce the results of a pre-feasibility study (“Jay PFS”) on the Jay kimberlite pipe deposit located within the Buffer Zone Joint Venture property in Canada’s Northwest Territories.
Sign-up for Dominion Diamond Corporation Announces Jay Project Pre-Feasibility Study Results investment picks
2014/12/23
RESEARCH TRIANGLE PARK, N.C., Dec.
Sign-up for BioCryst Announces Study Results for BCX4430 in a Non-Human Primate Model of Ebola Virus Infection investment picks
2015/1/20
Trovagene's proprietary KRAS assay enables physicians to determine mutational status, monitor treatment response, and use genomics to aid in predicting patient prognosis SAN DIEGO , Jan.
Sign-up for Clinical Study Results Presented at the 2015 Gastrointestinal Cancer Symposium Support Utility of Trovagene's Precision Cancer Monitoring Platform in Colorectal and Pancreatic Cancer Patients investment picks
2015/2/17
- Data highlights the use and potential of PEGPH20 to enhance the anti-cancer activity of monoclonal antibodies and NK cell access in breast and ovarian cancer preclinical models - SAN DIEGO , Feb.
Sign-up for Halozyme Announces Preclinical Study Results Of PEGPH20 Published In Molecular Cancer Therapeutics investment picks

Premium Membership: Features and Benefits
Wide-Moat Screener for Stocks

Put a moat around your portfolio. Sniff out the most promising opportunities that can ride through any market.

Gold Medalist Screener for Funds

Narrow the available universe of 5000 funds to the top rated gold and silver. Then, sort for manager tenure, expense ratio, risk and return to create your own index-beating fund watchlist.

Thousands of Premium Analyst Reports

While many of our competitors measure a stock's worth with a computer program, Morningstar's staff of 150+ analyst sift through company fillings, financial data and a wealth of other sources to deliver an unvarnished review of any investment. In fact, twelve Morningstar analysts have been recognized by WSJ as "Best on the Street" in the US.

Premium Portfolio Monitor

Make decisions with confidence. Load your investments into our research center and automatically connect to all our proprietary tools and data points.

Mobile

Never be without critical research. Free with your active membership, take our Premium data and guidance wherever you go with Morningstar for iPad®, iPhone®, and Android apps.

Morningstar's Guarantee

We're looking out for you. If after your 14-day free trial, you find that a Morningstar Premium membership is not for you, cancel any time and we'll be happy to refund the unused portion - no questions asked.

Go Premium!
Exclusive Premium Member Benefits
Get the best thinking of 150+ disciplined
objective, experienced analysts-dedicated to
specific industries and securities.
+2,500 Analyst Reports
Wide Moat Screener for Stocks
Medalist Screener for Funds
Premium Portfolio Manager with X-Ray & Monitor
Premium eNewsletters
Morningstar Basic Benefits (All)
Sign up now - No charge for the first 14 days
Study Results
Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol |  Title Star Rating |  Category |  Total Assets |  Top Holdings |  Top Sectors |  Symbol |  Name Title |  Date |  Author |  Collection |  Interest |  Popularity Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol / Ticker |  Title Star Rating |  Category |  Total Assets |  Symbol / Ticker |  Name Title |  Date |  Author |  Collection |  Popularity |  Interest Title |  Date |  Company |  Symbol |  Interest |  Popularity Title |  Date |  Company |  Symbol |  Interest |  Popularity Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Popularity |  Our Choices |  Most Recent Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry |  Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry

Previous: Strongest Companies  |  Next: Subject Companies